Seek Returns

BMY vs. VTRS: Bristol-Myers Squibb vs. Viatris Stock Comparison

How do Bristol-Myers Squibb (BMY) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bristol-Myers Squibb (BMY) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
Profile ItemBMYVTRS
NameBristol-Myers Squibb CompanyViatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization127.02 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJune 1, 1972March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BMY
VTRS
GSPC
Loading price history…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bristol-Myers Squibb (BMY) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bristol-Myers Squibb (BMY) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Total Return (1Y)38.62%108.98%
Total Return (3Y, Annualized)12.29%36.75%
Total Return (5Y, Annualized)5.09%11.59%

Risk Profile

Drawdown History

BMY
VTRS
GSPC
Loading price history…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bristol-Myers Squibb (BMY) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Volatility (1Y, Annualized)28.01%32.53%
Beta (5Y)0.190.86
Max Drawdown (5Y)-47.67%-45.69%
Avg. Volume (3M)10.85M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BMY and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Sharpe Ratio (1Y)1.233.22
Sortino Ratio (1Y)1.955.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bristol-Myers Squibb (BMY) reports 44.01%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.01%

Max
109.18%
BMY
44.01%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Bristol-Myers Squibb (BMY) reports 18.47%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.47%

BMY
18.47%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.79%

Max
83.12%
BMY
33.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
ROE (TTM)44.01%-4.21%
ROA (TTM)10.90%2.91%
Net Margin (TTM)18.47%-4.13%
Operating Margin (TTM)33.79%13.85%
Gross Margin (TTM)70.50%41.13%

Growth

Revenue Growth

Bristol-Myers Squibb (BMY) at -0.22% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Bristol-Myers Squibb (BMY) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Revenue Growth (YoY)-0.22%-2.98%
Revenue Growth (3Y CAGR)1.45%-4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)5.46%--

Financial Strength

Current Ratio (MRQ)

Both Bristol-Myers Squibb (BMY) at 1.59 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.59

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BMY
1.59
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: Viatris (VTRS) at 0.99 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.91

BMY
1.91
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Current Ratio (MRQ)1.591.55
Debt / Equity (MRQ)1.910.99
Net Debt / EBITDA1.772.64

Dividends

Dividend Yield (TTM)

Both Bristol-Myers Squibb (BMY) at 3.99% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.99%

BMY
3.99%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bristol-Myers Squibb (BMY) reports 55.88%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.88%

BMY
55.88%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
Dividend Yield (TTM)3.99%2.53%
Dividend Payout Ratio (TTM)55.88%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Bristol-Myers Squibb (BMY) trades at 13.78 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.78

Max
85.34
Q3
43.46
Median
26.69
BMY
13.78
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; BMY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Both Bristol-Myers Squibb (BMY) at 2.54 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.54

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
BMY
2.54
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Bristol-Myers Squibb (BMY) at 5.43 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.43

Max
13.53
Q3
6.54
BMY
5.43
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Bristol-Myers Squibb (BMY) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bristol-Myers Squibb (BMY) and Viatris (VTRS)
MetricBMYVTRS
P/E Ratio (TTM)13.78--
P/S Ratio (TTM)2.541.55
P/B Ratio (MRQ)5.431.67
Free Cash Flow Yield (TTM)5.01%13.84%